Obesity in renal transplantation: The role of induction therapy on long-term outcomes

S. Patel, O. Pankewycz, R. Kohli, M. Said, Muna A Alnimri, L. Feng, M. R. Laftavi

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Obesity is a burgeoning problem among renal transplant recipients given its association with increased morbidity, graft loss, and mortality. The long-term influence of different induction therapies in obese compared to nonobese patients is uncertain. We examined the long-term effect of low-dose rabbit antithymocyte globulin (rATG; 35 mg/kg) induction therapy compared to two doses of 20 mg basiliximab (BSX) in nonobese and obese renal transplant patients. The medical records of all adult (>18 years) recipients of kidney transplants between June 2001 and June 2009 in our center were reviewed. Patients whose body mass index (BMI) was greater than 30 were considered to be obese. The average dose of rATG was 3.2 ± 1.6 mg/kg. A total of 475 patients were included. In the nonobese group with a BMI less than 30, 68 received BSX and 247, rATG. In the obese group, 27 patients were given BSX and 133 were given rATG. Mean follow-up was 1523 days. These four groups were similar in baseline characteristics including: donor and recipient age, percent diabetes, living donors, panel-reactive antibodies > 35, HLA mismatch, race, gender, and maintenance immunosuppression. Serum creatinine levels at 3 months and 1, 5, and 7 years were not statistically different between groups. Compared to BSX induction therapy, rATG was associated with better graft survival at 47.4 ± 10 months in obese (63.6% vs 90.3%, P < .05, respectively) as well as nonobese patients (68.2% vs 88.7%, P < .05, respectively). Rejections were numerically lower in rATG-treated obese patients, which reached statistical significance in nonobese patients. Wound and viral infections were not statistically different between rATG and BSX groups. Therefore, low-dose rATG is associated with a better long-term graft survival rate in obese patients without incurring an increased risk of infectious complications. When rATG was used in obese and nonobese patients, there was no difference in graft and patient survival.

Original languageEnglish (US)
Pages (from-to)469-471
Number of pages3
JournalTransplantation Proceedings
Volume43
Issue number2
DOIs
StatePublished - Mar 2011
Externally publishedYes

Fingerprint

Kidney Transplantation
Obesity
Graft Survival
Therapeutics
Kidney
Body Mass Index
Transplants
Antilymphocyte Serum
Living Donors
Virus Diseases
Wound Infection
Immunosuppression
Medical Records
Creatinine
Survival Rate
Maintenance
basiliximab
Tissue Donors
Rabbits
Morbidity

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Obesity in renal transplantation : The role of induction therapy on long-term outcomes. / Patel, S.; Pankewycz, O.; Kohli, R.; Said, M.; Alnimri, Muna A; Feng, L.; Laftavi, M. R.

In: Transplantation Proceedings, Vol. 43, No. 2, 03.2011, p. 469-471.

Research output: Contribution to journalArticle

Patel, S. ; Pankewycz, O. ; Kohli, R. ; Said, M. ; Alnimri, Muna A ; Feng, L. ; Laftavi, M. R. / Obesity in renal transplantation : The role of induction therapy on long-term outcomes. In: Transplantation Proceedings. 2011 ; Vol. 43, No. 2. pp. 469-471.
@article{041ebb14a73f45f2988f5c22eeae88a1,
title = "Obesity in renal transplantation: The role of induction therapy on long-term outcomes",
abstract = "Obesity is a burgeoning problem among renal transplant recipients given its association with increased morbidity, graft loss, and mortality. The long-term influence of different induction therapies in obese compared to nonobese patients is uncertain. We examined the long-term effect of low-dose rabbit antithymocyte globulin (rATG; 35 mg/kg) induction therapy compared to two doses of 20 mg basiliximab (BSX) in nonobese and obese renal transplant patients. The medical records of all adult (>18 years) recipients of kidney transplants between June 2001 and June 2009 in our center were reviewed. Patients whose body mass index (BMI) was greater than 30 were considered to be obese. The average dose of rATG was 3.2 ± 1.6 mg/kg. A total of 475 patients were included. In the nonobese group with a BMI less than 30, 68 received BSX and 247, rATG. In the obese group, 27 patients were given BSX and 133 were given rATG. Mean follow-up was 1523 days. These four groups were similar in baseline characteristics including: donor and recipient age, percent diabetes, living donors, panel-reactive antibodies > 35, HLA mismatch, race, gender, and maintenance immunosuppression. Serum creatinine levels at 3 months and 1, 5, and 7 years were not statistically different between groups. Compared to BSX induction therapy, rATG was associated with better graft survival at 47.4 ± 10 months in obese (63.6{\%} vs 90.3{\%}, P < .05, respectively) as well as nonobese patients (68.2{\%} vs 88.7{\%}, P < .05, respectively). Rejections were numerically lower in rATG-treated obese patients, which reached statistical significance in nonobese patients. Wound and viral infections were not statistically different between rATG and BSX groups. Therefore, low-dose rATG is associated with a better long-term graft survival rate in obese patients without incurring an increased risk of infectious complications. When rATG was used in obese and nonobese patients, there was no difference in graft and patient survival.",
author = "S. Patel and O. Pankewycz and R. Kohli and M. Said and Alnimri, {Muna A} and L. Feng and Laftavi, {M. R.}",
year = "2011",
month = "3",
doi = "10.1016/j.transproceed.2011.01.040",
language = "English (US)",
volume = "43",
pages = "469--471",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "2",

}

TY - JOUR

T1 - Obesity in renal transplantation

T2 - The role of induction therapy on long-term outcomes

AU - Patel, S.

AU - Pankewycz, O.

AU - Kohli, R.

AU - Said, M.

AU - Alnimri, Muna A

AU - Feng, L.

AU - Laftavi, M. R.

PY - 2011/3

Y1 - 2011/3

N2 - Obesity is a burgeoning problem among renal transplant recipients given its association with increased morbidity, graft loss, and mortality. The long-term influence of different induction therapies in obese compared to nonobese patients is uncertain. We examined the long-term effect of low-dose rabbit antithymocyte globulin (rATG; 35 mg/kg) induction therapy compared to two doses of 20 mg basiliximab (BSX) in nonobese and obese renal transplant patients. The medical records of all adult (>18 years) recipients of kidney transplants between June 2001 and June 2009 in our center were reviewed. Patients whose body mass index (BMI) was greater than 30 were considered to be obese. The average dose of rATG was 3.2 ± 1.6 mg/kg. A total of 475 patients were included. In the nonobese group with a BMI less than 30, 68 received BSX and 247, rATG. In the obese group, 27 patients were given BSX and 133 were given rATG. Mean follow-up was 1523 days. These four groups were similar in baseline characteristics including: donor and recipient age, percent diabetes, living donors, panel-reactive antibodies > 35, HLA mismatch, race, gender, and maintenance immunosuppression. Serum creatinine levels at 3 months and 1, 5, and 7 years were not statistically different between groups. Compared to BSX induction therapy, rATG was associated with better graft survival at 47.4 ± 10 months in obese (63.6% vs 90.3%, P < .05, respectively) as well as nonobese patients (68.2% vs 88.7%, P < .05, respectively). Rejections were numerically lower in rATG-treated obese patients, which reached statistical significance in nonobese patients. Wound and viral infections were not statistically different between rATG and BSX groups. Therefore, low-dose rATG is associated with a better long-term graft survival rate in obese patients without incurring an increased risk of infectious complications. When rATG was used in obese and nonobese patients, there was no difference in graft and patient survival.

AB - Obesity is a burgeoning problem among renal transplant recipients given its association with increased morbidity, graft loss, and mortality. The long-term influence of different induction therapies in obese compared to nonobese patients is uncertain. We examined the long-term effect of low-dose rabbit antithymocyte globulin (rATG; 35 mg/kg) induction therapy compared to two doses of 20 mg basiliximab (BSX) in nonobese and obese renal transplant patients. The medical records of all adult (>18 years) recipients of kidney transplants between June 2001 and June 2009 in our center were reviewed. Patients whose body mass index (BMI) was greater than 30 were considered to be obese. The average dose of rATG was 3.2 ± 1.6 mg/kg. A total of 475 patients were included. In the nonobese group with a BMI less than 30, 68 received BSX and 247, rATG. In the obese group, 27 patients were given BSX and 133 were given rATG. Mean follow-up was 1523 days. These four groups were similar in baseline characteristics including: donor and recipient age, percent diabetes, living donors, panel-reactive antibodies > 35, HLA mismatch, race, gender, and maintenance immunosuppression. Serum creatinine levels at 3 months and 1, 5, and 7 years were not statistically different between groups. Compared to BSX induction therapy, rATG was associated with better graft survival at 47.4 ± 10 months in obese (63.6% vs 90.3%, P < .05, respectively) as well as nonobese patients (68.2% vs 88.7%, P < .05, respectively). Rejections were numerically lower in rATG-treated obese patients, which reached statistical significance in nonobese patients. Wound and viral infections were not statistically different between rATG and BSX groups. Therefore, low-dose rATG is associated with a better long-term graft survival rate in obese patients without incurring an increased risk of infectious complications. When rATG was used in obese and nonobese patients, there was no difference in graft and patient survival.

UR - http://www.scopus.com/inward/record.url?scp=79953206620&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953206620&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2011.01.040

DO - 10.1016/j.transproceed.2011.01.040

M3 - Article

C2 - 21440736

AN - SCOPUS:79953206620

VL - 43

SP - 469

EP - 471

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 2

ER -